Friday 6 November 2026 Export RYTM’s income statement to Excel — free account

Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.

Revenue: +79.6%
EPS: +26.9%
Free cash flow: +95.4%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

112.38 7.36 +7.01%

Follow RYTM

Alert me

Market cap: $7.3B
P/E: 0.0×
Fwd P/E: −31.6×
Dividend yield: —
F-score: 6/9
Altman Z: 15.89
Beneish M: −2.93
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Rhythm Pharmaceuticals, Inc. (RYTM) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Rhythm Pharmaceuticals, Inc. (RYTM) trades at a P/S ratio of 25.5×. Over the past ten years it has ranged from 0.0× (December 2021) to 192× (March 2022); the current reading is higher than 53% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RYTM/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Rhythm Pharmaceuticals, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RYTM/metrics/ps-ratio">Rhythm Pharmaceuticals, Inc. (RYTM) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	36.7×	39.70%
FY2024	26.2×	(21.94%)
FY2023	33.6×	(46.77%)
FY2022	63.2×	(59.76%)
FY2021	157×	—

Period	P/S ratio	Change
Sep 2026	23.4×	(26.23%)
Jun 2026	31.7×	16.61%
Mar 2026	27.2×	(25.74%)
Dec 2025	36.7×	(4.50%)
19 more quarters	Free account

Against its own ten years

Low 0.0× High 192×

Ten-year median 23.1×

Current reading's percentile 11

Company	P/S ratio
ABVX Abivax SA Sponsored ADR compare	n/m
ORKA Oruka Therapeutics, Inc. compare	n/m
IONS Ionis Pharmaceuticals, Inc. compare	7.4×
AXSM Axsome Therapeutics, Inc. compare	7.8×
CORT Corcept Therapeutics Incorporated compare	8.0×
ARWR Arrowhead Pharmaceuticals, Inc. compare	12.3×
RYTM Rhythm Pharmaceuticals, Inc.	25.5×
CYTK Cytokinetics, Incorporated compare	64.4×
PRAX Praxis Precision Medicines, Inc. compare	901×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Rhythm Pharmaceuticals, Inc. (RYTM) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RYTM

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RYTM

Stockrow Weekly